1. Home
  2. SLGB vs IMA Comparison

SLGB vs IMA Comparison

Compare SLGB & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SLGB

Smart Logistics Global Limited Ordinary Shares

N/A

Current Price

$0.90

Market Cap

56.3M

Sector

Industrials

ML Signal

N/A

IMA

ImageneBio Inc.

HOLD

Current Price

$5.98

Market Cap

54.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLGB
IMA
Founded
2017
2019
Country
Hong Kong
United States
Employees
N/A
15
Industry
Integrated Freight & Logistics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3M
54.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLGB
IMA
Price
$0.90
$5.98
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
921.7K
391.7K
Earning Date
05-16-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$3.94
52 Week High
$6.02
$17.50

Technical Indicators

Market Signals
Indicator
SLGB
IMA
Relative Strength Index (RSI) 46.35 58.05
Support Level $0.60 $5.52
Resistance Level $1.20 $7.04
Average True Range (ATR) 0.12 0.45
MACD 0.03 0.17
Stochastic Oscillator 49.59 71.74

Price Performance

Historical Comparison
SLGB
IMA

About SLGB Smart Logistics Global Limited Ordinary Shares

Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: